- Sanofi SA Sponsored ADR (SAN) lifted its 2026 outlook: now targeting about 10% CER sales growth and forecasted business EPS to rise slightly faster than sales on a CER basis.
- Sanofi (SAN) reshuffled executives, named a new R&D chief, stopped regulatory filings for an acquired eczema drug, and halted development of two other programs, affecting its R&D pipeline.
TradingView
Key facts: Sanofi (SAN) ups 2026 outlook; R&D reshuffle halts projects
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- EURONEXT:SAN
- Language
- English (India)
Sanofi SA Sponsored ADR (SAN) lifted its 2026 outlook: now targeting about 10% CER sales growth and forecasted business EPS to rise slightly faster than sales on a CER basis.Sanofi